91345
document
The cognitive , subjective , and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints . We evaluated the effects of a Ginkgo biloba/ginseng combination on cognitive function in this 90-day , double-blind , placebo-controlled , parallel-group study . Sixty-four healthy volunteers ( aged 40 to 65 years ) , selected on the basis of fulfilling the ICD-10 F48.0 criteria for neurasthenia , were assigned randomly to four equal dosing groups , receiving 80 , 160 , or 320 mg of the combination b.i.d . or placebo . Assessments were performed on the day before dosing , and again at Days 1 , 30 , and 90 at 1 hour after the morning dose and 1 hour after the afternoon dose . The assessments included the Cognitive Drug Research ( CDR ) computerized assessment system , the Vienna Determination Unit , cycle ergometry , and various questionnaires . The treatments were well tolerated by all volunteers . On Day 90 at 1 hour post morning dosing , dose-related improvements were seen on the CDR tests , the 320 mg dose being significantly superior to placebo . These effects , however , were reversed 1 hour after the afternoon dose , possibly suggesting that a longer inter-dosing interval would be preferable . The 80-mg dose produced a significant benefit on the ergometry assessment of heart rate at maximum load . There were also several supporting changes from other assessments , including an advantage of 320 mg over placebo on the global score from the Symptom Checklist-90-revised ( SCL-90-R ) at Day 90 .
91346
Intervention_Pharmacological
ginkgo biloba/panax ginseng combination
91347
Intervention_Pharmacological
Ginkgo biloba/ginseng combination
91348
Intervention_Control
placebo-controlled
91349
Intervention_Control
placebo
91350
Intervention_Control
placebo
91351
Outcome_Physical
cognitive , subjective , and physical effects
91352
Outcome_Other
effects
91353
Outcome_Mental
cognitive function
91354
Outcome_Mental
Cognitive Drug Research ( CDR ) computerized assessment system
91355
Outcome_Mental
the Vienna Determination Unit
91356
Outcome_Other
cycle ergometry , and various questionnaires
91357
Outcome_Other
well tolerated
91358
Outcome_Other
dose-related improvements
91359
Outcome_Physical
ergometry assessment of heart rate
91360
Participant_Condition
healthy volunteers with neurasthenic complaints .
91361
Participant_Sample-size
Sixty-four healthy volunteers
91362
Participant_Age
aged 40 to 65 years )
91363
Participant_Condition
criteria for neurasthenia